(Reuters) -Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and ...

Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two ...

Mounjaro reduces major heart problems by 8% versus Trulicity in trial Death from any cause was 16% lower for patients on Mounjaro versus Trulicity Safety profile similar for both drugs July 31 ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity. Stream ...